Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors
September 19 2019 - 7:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced
that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis
Board of Directors. Dr. Onetto brings over 20 years of oncology
drug development experience to the Board.
“Dr. Onetto’s broad experience in oncology and
hematology will be invaluable to Sunesis as we develop our kinase
inhibitor pipeline, including our lead asset, the
non-covalent BTK inhibitor vecabrutinib,” said Dayton
Misfeldt, Interim Chief Executive Officer of Sunesis. “Dr.
Onetto brings to Sunesis a distinguished career with a wealth of
experience operationally and strategically in developing and
bringing novel and innovative oncology drugs to patients. We
welcome Dr. Onetto to the board and look forward to benefitting
from her expertise."
“I’m pleased to join the Sunesis board of
directors at such a pivotal time in the clinical development of
vecabrutinib and look forward to working with the management team
to advance the development of Sunesis’ portfolio of kinase
inhibitors,” said Dr. Onetto.
Dr. Onetto is an expert in oncology drug
development and translational research. She was most recently
Deputy Director and Chief Scientific Officer at the Ontario
Institute for Cancer Research (OICR) from 2009 to 2016. Before her
work at OICR, she was Senior Vice President and Chief Medical
Officer at ZymoGenetics from 2005 to 2009. Prior to joining
ZymoGenetics, she served as Executive Vice President Oncology, and
then as Chief Medical Officer and Executive Vice President at OSI
Pharmaceuticals from 2002 to 2005. With her team she led the
worldwide registration program for Tarceva, one of the first
targeted therapies approved for treating cancer patients. Her
career in the pharmaceutical industry also includes senior
management positions at Bristol-Myers Squibb, Gilead Sciences,
Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, and
Immunex. At Bristol Myers Squibb, among other
responsibilities, she was the worldwide project leader for
Taxol.
Dr. Onetto is currently a member of the board of
Basilea Pharmaceutica, Sierra Oncology, and NBE Therapeutics.
Previously she served for eleven years as a board member of
ImmunoGen. Dr. Onetto received her M.D. from the University of
Paris and a Master of Pharmacology from the University of
Montréal.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing novel targeted inhibitors for the treatment of
hematologic and solid cancers. Sunesis has built an experienced
drug development organization committed to improving the lives of
people with cancer. The Company is focused on advancing its novel
kinase inhibitor pipeline, with an emphasis on its oral
non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently
being evaluated in a Phase 1b/2 study in adults with chronic
lymphocytic leukemia and other B-cell malignancies that have
progressed after prior therapies.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
This press release contains forward-looking
statements, , including statements related to the continued
development of vecabrutinib (SNS-062). Words such as "may,"
“intend,” “will,” “potential,” “look forward,” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Sunesis' current
expectations. Forward-looking statements involve risks and
uncertainties. Sunesis' actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties. These and other risk factors are discussed under
"Risk Factors" in Sunesis' Quarterly Report on Form 10-Q for the
quarter ended June 30, 2019 and Sunesis' other filings
with the Securities and Exchange Commission. Sunesis expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Sunesis' expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based.
Investor and Media
Inquiries:Maeve ConneightonArgot Partners212-600-1902 |
Willie
QuinnSunesis Pharmaceuticals Inc.650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024